These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29380227)

  • 21. An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings.
    MacQueen KM; Tolley EE; Owen DH; Amico KR; Morrow KM; Moench T; Friend DR; Friedland B
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19158. PubMed ID: 25224617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virtual intervention to support self-management of antiretroviral therapy among people living with HIV.
    Côté J; Godin G; Ramirez-Garcia P; Rouleau G; Bourbonnais A; Guéhéneuc YG; Tremblay C; Otis J
    J Med Internet Res; 2015 Jan; 17(1):e6. PubMed ID: 25563775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
    Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
    BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring 'generative mechanisms' of the antiretroviral adherence club intervention using the realist approach: a scoping review of research-based antiretroviral treatment adherence theories.
    Mukumbang FC; Van Belle S; Marchal B; van Wyk B
    BMC Public Health; 2017 May; 17(1):385. PubMed ID: 28472938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Association of HIV-Related Stigma to HIV Medication Adherence: A Systematic Review and Synthesis of the Literature.
    Sweeney SM; Vanable PA
    AIDS Behav; 2016 Jan; 20(1):29-50. PubMed ID: 26303196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa.
    Musinguzi N; Muganzi CD; Boum Y; Ronald A; Marzinke MA; Hendrix CW; Celum C; Baeten JM; Bangsberg DR; Haberer JE;
    AIDS; 2016 Apr; 30(7):1121-9. PubMed ID: 26785125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral therapy drug adherence in Rwanda: perspectives from patients and healthcare workers using a mixed-methods approach.
    Vyankandondera J; Mitchell K; Asiimwe-Kateera B; Boer K; Mutwa P; Balinda JP; van Straten M; Reiss P; van de Wijgert J
    AIDS Care; 2013; 25(12):1504-12. PubMed ID: 23517180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
    Hankins CA; Dybul MR
    Curr Opin HIV AIDS; 2013 Jan; 8(1):50-8. PubMed ID: 23201856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral adherence interventions: translating research findings to the real world clinic.
    Simoni JM; Amico KR; Smith L; Nelson K
    Curr HIV/AIDS Rep; 2010 Feb; 7(1):44-51. PubMed ID: 20425057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Actionable Adherence Monitoring: Technological Methods to Monitor and Support Adherence to Antiretroviral Therapy.
    Bell KM; Haberer JE
    Curr HIV/AIDS Rep; 2018 Oct; 15(5):388-396. PubMed ID: 30232578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation.
    Liu AY; Hessol NA; Vittinghoff E; Amico KR; Kroboth E; Fuchs J; Irvin R; Sineath RC; Sanchez T; Sullivan PS; Buchbinder SP
    AIDS Patient Care STDS; 2014 Dec; 28(12):622-7. PubMed ID: 25396706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review of adherence to oral pre-exposure prophylaxis for HIV - how can we improve uptake and adherence?
    Sidebottom D; Ekström AM; Strömdahl S
    BMC Infect Dis; 2018 Nov; 18(1):581. PubMed ID: 30445925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations between perceived barriers and benefits of using HIV pre-exposure prophylaxis and medication adherence among men who have sex with men in Western China.
    Hu Y; Zhong XN; Peng B; Zhang Y; Liang H; Dai JH; Zhang JY; Huang AL
    BMC Infect Dis; 2018 Nov; 18(1):575. PubMed ID: 30442106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.
    Koester KA; Liu A; Eden C; Amico KR; McMahan V; Goicochea P; Hosek S; Mayer KH; Grant RM
    AIDS Care; 2015; 27(10):1199-204. PubMed ID: 26001026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Adherence to HIV Pre-Exposure Prophylaxis among Veterans.
    Huang M; Liu W; Plomondon ME; Prochazka AV; Bessesen MT
    J Gen Intern Med; 2018 Mar; 33(3):253-255. PubMed ID: 29302884
    [No Abstract]   [Full Text] [Related]  

  • 38. Short message service (SMS) reminders and real-time adherence monitoring improve antiretroviral therapy adherence in rural Uganda.
    Haberer JE; Musiimenta A; Atukunda EC; Musinguzi N; Wyatt MA; Ware NC; Bangsberg DR
    AIDS; 2016 May; 30(8):1295-300. PubMed ID: 26760452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV pre-exposure prophylaxis (PrEP).
    Tumarkin E; Siedner MJ; Bogoch II
    BMJ; 2019 Jan; 364():k4681. PubMed ID: 30655299
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.